Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory biomarker study in Phase III trial of mFOLFOX6 + bevacizumab vs mFOLFOX6 + panitumumab in RAS wild-type unresectable colorectal cancer
jRCT1080222785Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of panitumumab, bevacizumab, fluorouracil, levoleucovorin and oxaliplatin in colorectal cancer (CRC) (2 arms), sponsored by Takeda. Primary endpoints: Treatment sensitivity factors and Prognostic factors. Started Mar 2015; status: completed.
02
Drugs
panitumumabbevacizumabfluorouracillevoleucovorinoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT1080222785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222785.